Tolerability of Nab-Paclitaxel Plus Gemcitabine as Adjuvant Setting in Japanese Patients With Resected Pancreatic Cancer
Authors:
- Makoto UenoMUMakoto Ueno
- Soichiro MorinagaSMSoichiro Morinaga
- Yusuke HashimotoYHYusuke Hashimoto
- Kumiko UmemotoKUKumiko Umemoto
- Naoki SasahiraNSNaoki Sasahira
- Akio SaiuraASAkio Saiura
- Yasuji SeyamaYSYasuji Seyama
- Goro HondaGHGoro Honda
- Tatsuya IokaTITatsuya Ioka
- Hidenori TakahashiHTHidenori Takahashi
- Atsushi MiyamotoAMAtsushi Miyamoto
- Shoji NakamoriSNShoji Nakamori
Open Access
- 1 January 2021
- journal article
- research article
- Published by Wolters Kluwer Health in Pancreas
- Vol. 50 (1) , 83-88
Abstract
Objective: The combination of gemcitabine plus nab-paclitaxel (GnP) has not been studied in Japanese patients with resectable pancreatic cancer (PC). This study aimed to assess the tolerability of adjuvant GnP in Japanese patients with resected PC. Methods: This was a Phase I, open-label, multicenter, single-arm study of patients with resected PC in Japan. Patients received 125 mg/m2 of nab-paclitaxel and 1000 mg/m2 of gemcitabine on days 1, 8, and 15 of a 28-day cycle for a total of 6 cycles. The primary end point was tolerability, defined as the absence of specific grade 3 or higher treatment-related adverse events by the end of cycle 2. Secondary end points included safety, disease-free survival, and overall survival. Results: Forty-one patients were enrolled between June 2016 and February 2017 (median age, 68 years; 51% male; stage II, 95%). Gemcitabine plus nab-paclitaxel met the tolerability criteria in 39 of the 40 patients included in the tolerability analysis set (97.5%). The most common treatment-related adverse events were leukopenia, neutropenia, alopecia, and peripheral sensory neuropathy. After a follow-up of 30.1 months, median disease-free survival was 17.0 months and median overall survival was not reached. Conclusions: These results show that adjuvant GnP is tolerable in Japanese patients with resected PC. Clinical Trial Registration No.: JapicCTI-163179Keywords
This publication has 17 references indexed in Scilit:
- Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01)The Lancet, 2016
- Phase I/II study of nab-paclitaxel plus gemcitabine for chemotherapy-naive Japanese patients with metastatic pancreatic cancerCancer Chemotherapy and Pharmacology, 2016
- Incidence and risk of peripheral neuropathy with nab-paclitaxel in patients with cancer: a meta-analysisEuropean Journal of Cancer Care, 2015
- Addressing the challenges of pancreatic cancer: Future directions for improving outcomesPancreatology, 2015
- Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus GemcitabineNew England Journal of Medicine, 2013
- Adjuvant Chemotherapy With Gemcitabine and Long-term Outcomes Among Patients With Resected Pancreatic CancerJAMA, 2013
- Stromal disrupting effects of nab-paclitaxel in pancreatic cancerBritish Journal of Cancer, 2013
- Adjuvant Chemotherapy With Fluorouracil Plus Folinic Acid vs Gemcitabine Following Pancreatic Cancer ResectionJAMA, 2010
- Adjuvant Chemotherapy With Gemcitabine vs Observation in Patients Undergoing Curative-Intent Resection of Pancreatic CancerJAMA, 2007
- A Randomized Trial of Chemoradiotherapy and Chemotherapy after Resection of Pancreatic CancerNew England Journal of Medicine, 2004